CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer

Jihye Kim, Young Jae Cho, Ji Yoon Ryu, Ilseon Hwang, Hee Dong Han, Hyung Jun Ahn, Woo Young Kim, Hanbyoul Cho, Joon Yong Chung, Stephen M. Hewitt, Jae Hoon Kim, Byoung Gie Kim, Duk Soo Bae, Chel Hun Choi, Jeong Won Lee

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)

Abstract

Objective: Cyclin-dependent kinase 7 (CDK7) engages tumor growth by acting as a direct link between the regulation of transcription and the cell cycle. Here, we investigated the clinical significance of CDK7 expression and its potential as a therapeutic target in epithelial ovarian cancer (EOC). Methods: CDK7 expression was examined in 436 ovarian tissues including normal to metastatic ovarian tumors using immunohistochemistry, and its clinical implications were analyzed. Furthermore, we performed in vitro and in vivo experiments using CDK7 siRNA or a covalent CDK7 inhibitor (THZ1) to elucidate the effect of CDK7 inhibition on tumorigenesis in EOC cells. Results: The patient incidence of high CDK7 expression (CDK7High) gradually increased from normal ovarian epithelium to EOC (P < 0.001). Moreover, CDK7High was associated with an advanced stage and high-grade histology (P = 0.035 and P = 0.011, respectively) in EOC patients and had an independent prognostic significance in EOC recurrence (P = 0.034). CDK7 inhibition with siRNA or THZ1 decreased cell proliferation and migration, and increased apoptosis in EOC cells, and this anti-cancer mechanism is caused by G0/G1 cell cycle arrest. In in vivo therapeutic experiments using cell-line xenograft and PDX models, CDK7 inhibition significantly decreased the tumor weight, which was mediated by cell proliferation and apoptosis. Conclusion: Mechanistic interrogation of CDK7 revealed that it is significantly associated with an aggressive phenotype of EOC, and it has independent prognostic power for EOC recurrence. Furthermore, CDK7 may be a potential therapeutic target for patients with EOC, whether platinum sensitive or resistant.

Original languageEnglish
Pages (from-to)211-221
Number of pages11
JournalGynecologic Oncology
Volume156
Issue number1
DOIs
Publication statusPublished - 2020 Jan

Bibliographical note

Publisher Copyright:
© 2019 Elsevier Inc.

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Fingerprint

Dive into the research topics of 'CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer'. Together they form a unique fingerprint.

Cite this